|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48.
2023.PubMed/NCBI
|
|
2
|
Zhu H, Ma X, Ye T, Wang H, Wang Z, Liu Q
and Zhao K: Esophageal cancer in China: Practice and research in
the new era. Int J Cancer. 152:1741–1751. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu
Z, Mao W, Xiang J, Han Y, Chen Z, et al: Long-term efficacy of
neoadjuvant chemoradiotherapy plus surgery for the treatment of
locally advanced esophageal squamous cell carcinoma: The
NEOCRTEC5010 Randomized clinical trial. JAMA Surg. 156:721–729.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eyck BM, van Lanschot JJB, Hulshof MCCM,
van der Wilk BJ, Shapiro J, van Hagen P, van Berge Henegouwen MI,
Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, et al:
Ten-Year outcome of neoadjuvant chemoradiotherapy plus surgery for
esophageal cancer: The Randomized controlled CROSS trial. J Clin
Oncol. 39:1995–2004. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shapiro J, van Lanschot JJB, Hulshof MCCM,
van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven
HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, et al:
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for
oesophageal or junctional cancer (CROSS) Long-term results of a
randomised controlled trial. Lancet Oncol. 16:1090–1098. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu
Z, Mao W, Xiang J, Han Y, Chen Z, et al: Neoadjuvant
chemoradiotherapy followed by surgery versus surgery alone for
locally advanced squamous cell carcinoma of the esophagus
(NEOCRTEC5010): A phase III multicenter, Randomized, open-label
clinical trial. J Clin Oncol. 36:2796–2803. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan M, Bao Y, Ma Z, Men Y, Wang Y and Hui
Z: The optimal treatment for resectable esophageal cancer: A
network meta-analysis of 6168 patients. Front Oncol. 11:6287062021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hoeppner J, Brunner T, Lordick F, Glatz T,
Bronsert P, Röthling N, Schmoor C, Lorenz D, Ell C, Hopt UT and
Siewert JR: Prospective randomized multicenter phase III trial
comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant
chemoradiation (CROSS protocol) in patients with adenocarcinoma of
the esophagus (ESOPEC trial). Journal of Clinical Oncol. 42:LBA1.
2024. View Article : Google Scholar
|
|
9
|
Kato K, Machida R, Ito Y, Daiko H, Ozawa
S, Ogata T, Hara H, Kojima T, Abe T, Bamba T, et al: Doublet
chemotherapy, triplet chemotherapy, or doublet chemotherapy
combined with radiotherapy as neoadjuvant treatment for locally
advanced oesophageal cancer (JCOG1109 NExT): A randomised,
controlled, open-label, phase 3 trial. Lancet. 404:55–66. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mu Y, Wang H, He T and Xu L: The impact of
radiation dose on preoperative neoadjuvant chemoradiotherapy
effects for patients with locally advanced squamous cell esophageal
carcinoma: A propensity score-matched retrospective study. J
Immunol Res. 2022:75817992022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murakami Y, Hamai Y, Emi M, Hihara J,
Imano N, Takeuchi Y, Takahashi I, Nishibuchi I, Kimura T, Okada M
and Nagata Y: Long-term results of neoadjuvant chemoradiotherapy
using cisplatin and 5-fluorouracil followed by esophagectomy for
resectable, locally advanced esophageal squamous cell carcinoma. J
Radiat Res. 59:616–624. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang TC, Hsu CH, Lin CC and Tu YK:
Systematic review and network meta-analysis: Neoadjuvant
chemoradiotherapy for locoregional esophageal cancer. Jpn J Clin
Oncol. 45:1023–1028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, Zhu
Z, Zhao W, Lin Q, Yang H, et al: Comparison of 3 paclitaxel-based
chemoradiotherapy regimens for patients with locally advanced
esophageal squamous cell cancer: A Randomized clinical trial. JAMA
Netw Open. 5:e2201202022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang
Z, Yang Z and Zhou A: Encouraging pathological complete response
rate from neoadjuvant chemotherapy with albumin-bound paclitaxel
plus cisplatin and capecitabine for locally advanced esophageal
squamous carcinoma: Preliminary outcome of a retrospective study.
Cancer Manag Res. 13:2163–2170. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rice TW, Gress DM, Patil DT, Hofstetter
WL, Kelsen DP and Blackstone EH: Cancer of the esophagus and
esophagogastric junction-major changes in the American Joint
Committee on Cancer eighth edition cancer staging manual. CA Cancer
J Clin. 67:304–317. 2017.PubMed/NCBI
|
|
16
|
Schag CC, Heinrich RL and Ganz PA:
Karnofsky performance status revisited: Reliability, validity, and
guidelines. J Clin Oncol. 2:187–193. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang D, Zhang W, Qian D, Guan Y, Chen X,
Zhang H, Wang J and Pang Q: Efficacy and safety of weekly
nab-paclitaxel plus cisplatin with concurrent intensity-modulated
radiotherapy in patients with inoperable, locally advanced
esophageal cancer: A pilot trial. Onco Targets Ther. 11:6333–6338.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guan Z, Li QL, Feng F, Jiang Z, Shen Z, Yu
S, Fen J, Huang J, Yao Z and Bhar P: Superior efficacy of a
Cremophor-free albumin-bound paclitaxel compared with solvent-based
paclitaxel in Chinese patients with metastatic breast cancer. Asia
Pac J Clin Oncol. 5:165–174. 2009. View Article : Google Scholar
|
|
19
|
Mandard AM, Dalibard F, Mandard JC, Marnay
J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G,
et al: Pathologic assessment of tumor regression after preoperative
chemoradiotherapy of esophageal carcinoma. Clinicopathologic
correlations. Cancer. 73:2680–2686. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
National Cancer Institute and Division of
Cancer Treatment, . Diagnosis: Lead Organizations: NCI Network
Trial Development and Conduct. https://dctd.cancer.gov/research/ctep-trials/trial-development#ctc_archiveFebruary
12–2026
|
|
21
|
Seely AJ, Ivanovic J, Threader J,
Al-Hussaini A, Al-Shehab D, Ramsay T, Gilbert S, Maziak DE, Shamji
FM and Sundaresan RS: Systematic classification ofmorbidity and
mortality after thoracic surgery. Ann Thorac Surg. 90:936–942.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Logarajah S, Jeyarajah P, Darwish M,
Moslim M, Jureller M, Osman H and Jeyarajah DR: Does chemotherapy
regimen matter in the neoadjuvant treatment of esophageal cancer? J
Gastrointest Oncol. 13:2713–2720. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Münch S, Pigorsch SU, Feith M,
Slotta-Huspenina J, Weichert W, Friess H, Combs SE and Habermehl D:
Comparison of neoadjuvant chemoradiation with
carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with
squamous cell carcinoma of the esophagus. Radiat Oncol. 12:1822017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yi Q, Liu C, Cui Y, Yang Y, Li Y, Fan X
and Wu K: Chemoradiotherapy with paclitaxel liposome plus cisplatin
for locally advanced esophageal squamous cell carcinoma: A
retrospective analysis. Cancer Med. 12:6477–6487. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang L, Zhu J, Chen X, Wang Y, Wu L, Wan
G, Han Y, Leng X, Peng L and Wang Q: Safety and efficacy of
paclitaxel plus carboplatin versus paclitaxel plus cisplatin in
neoadjuvant chemoradiotherapy for patients with locally advanced
esophageal carcinoma: A retrospective study. Radiat Oncol.
17:2182022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen Y, Ye J, Zhu Z, Zhao W, Zhou J, Wu C,
Tang H, Fan M, Li L, Lin Q, et al: Comparing paclitaxel plus
fluorouracil versus cisplatin plus fluorouracil in
chemoradiotherapy for locally advanced esophageal squamous cell
cancer: A Randomized, multicenter, phase III clinical trial. J Clin
Oncol. 37:1695–1703. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang J, Bi N, Wu S, Chen M, Lv C, Zhao L,
Shi A, Jiang W, Xu Y, Zhou Z, et al: Etoposide and cisplatin versus
paclitaxel and carboplatin with concurrent thoracic radiotherapy in
unresectable stage III non-small cell lung cancer: A multicenter
randomized phase III trial. Ann Oncol. 28:777–783. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xin D, Song Y, Mu L, Zhang B, Qi L, Gao J,
Wang X, Xu J, Qu T and Huang J: The efficacy and safety of
nanoparticle albumin bound-paclitaxel-based regimen as second- or
third-line treatment in patients with advanced esophageal squamous
cell carcinoma. Thorac Cancer. 14:1392–1397. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Spigel DR, Jotte RM, Aix SP, Gressot L,
Morgensztern D, McCleod M, Socinski MA, Daniel D, Juan-Vidal O,
Mileham KF, et al: Nanoparticle albumin-bound paclitaxel plus
carboplatin induction followed by nanoparticle albumin-bound
paclitaxel maintenance in squamous non-small-cell lung cancer
(ABOUND.sqm): A phase III Randomized clinical trial. Clin Lung
Cancer. 22:6–15.e4. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoneshima Y, Morita S, Ando M, Nakamura A,
Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, et
al: Phase 3 trial comparing nanoparticle albumin-bound paclitaxel
with docetaxel for previously treated advanced NSCLC. J Thorac
Oncol. 16:1523–1532. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tu L, Sun L, Xu Y, Wang Y, Zhou L, Liu Y,
Zhu J, Peng F, Wei Y and Gong Y: Paclitaxel and cisplatin combined
with intensity-modulated radiotherapy for upper esophageal
carcinoma. Radiat Oncol. 8:752013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang J, Peng F, Li N, Liu Y, Xu Y, Zhou
L, Wang J, Zhu J, Huang M and Gong Y: Salvage concurrent
radio-chemotherapy for post-operative local recurrence of
squamous-cell esophageal cancer. Radiat Oncol. 7:932012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen J, Su T, Lin Y, Wang B, Li J, Pan J
and Chen C: Intensity-modulated radiotherapy combined with
paclitaxel and platinum treatment regimens in locally advanced
esophageal squamous cell carcinoma. Clin Transl Oncol. 20:411–419.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blom RL, Sosef MN, Nap M, Lammering G, van
den Berkmortel F, Hulshof MC, Meijer SL, Wilmink HW and van Berge
Henegouwen MI: Comparison of two neoadjuvant chemoradiotherapy
regimens in patients with potentially curable esophageal carcinoma.
Dis Esophagus. 27:380–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van Meerten E, Muller K, Tilanus HW,
Siersema PD, Eijkenboom WM, van Dekken H, Tran TC and van der Gaast
A: Neoadjuvant concurrent chemoradiation with weekly paclitaxel and
carboplatin for patients with oesophageal cancer: A phase II study.
Br J Cancer. 94:1389–1394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gaber CE, Sarker J, Abdelaziz AI, Okpara
E, Lee TA, Klempner SJ and Nipp RD: Pathologic complete response in
patients with esophageal cancer receiving neoadjuvant chemotherapy
or chemoradiation: A systematic review and meta-analysis. Cancer
Med. 13:e70762024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsuda S, Kawakubo H, Okamura A,
Takahashi K, Toihata T, Takemura R, Mayanagi S, Takeuchi H,
Watanabe M and Kitagawa Y: Prognostic significance of
stratification using pathological stage and response to neoadjuvant
chemotherapy for esophageal squamous cell carcinoma. Ann Surg
Oncol. 28:8438–8447. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wiesel O, Zlotnik O, Morgenstern S, Tsur
M, Menasherov N, Feferman Y, Ben-Aharon I and Kashtan H: Predicting
factors for a favorable pathologic response to neoadjuvant therapy
in esophageal cancer. Am J Clin Oncol. 45:514–518. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Komorowska D, Radzik T, Kalenik S and
Rodacka A: Natural radiosensitizers in radiotherapy: Cancer
treatment by combining ionizing radiation with resveratrol. Int J
Mol Sci. 23:106272022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wiedenmann N, Valdecanas D, Hunter N, Hyde
S, Buchholz TA, Milas L and Mason KA: 130-nm albumin-bound
paclitaxel enhances tumor radiocurability and therapeutic gain.
Clin Cancer Res. 13:1868–1874. 2007. View Article : Google Scholar : PubMed/NCBI
|
